SCR-LIP-000508 · Claim · machine-readable JSON →
In a systematic review of 16 studies covering 4537 lipedema patients, reported depression prevalence ranged from 23% to 59.2% (40% in the largest study, n=1362), with mean PHQ-9 scores of 10.8-12.2 (mild-to-moderate depression) and a suggested dose-response association with lipedema stage.
This single-paper claim was consolidated into general propositions (R-CLM-19); its evidence now sits under:
Claim at a glance
- Type
- clinical association
- Knowledge state
- Emerging
- Evidence certainty
- moderate (GRADE)
- Evidence
- 1 source(s)
- Answers
- 0 question(s)
- Dates
- 2026-11-17 → 2026-11-17
Structured evidence, machine-compiled — not a verdict.
Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-11-17
Evidence over time
Evidence (1)
- Lipedema and depression - A systematic review (2025) ✓ verified — consistent · review · 2025 · reading confidence: high
“Prevalências de depressão reportadas entre 23% e 59,2% Maior estudo (n=1362) reportou prevalência de 40% para depressão Vários estudos encontraram associação positiva entre depressão e estadiamento do lipedema — sugestivo de relação dose-resposta”
Systematic review reporting elevated depression prevalence and severity in lipedema patients versus general population, with a stage-dependent association, directly addressing the depression component of the question.
Context (PECO)
Answers these questions
- Not yet linked to a question.
Gaps & caveats
Auto-ingested single source; not yet human-reviewed.
Change log
- 2026-11-17 — created · auto-ingested for SQ-LIP-000020
- 2026-11-20 — consolidated · SQ-LIP-000020: evidence moved to SCR-LIP-000692
- 2026-11-20 — consolidated · SQ-LIP-000042: evidence moved to SCR-LIP-000785